Recombinant Anti-alpha 1 Fetoprotein antibody [EPR9309] (ab169552)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR9309] to alpha 1 Fetoprotein
- Suitable for: Flow Cyt (Intra), WB, IHC-P, ICC/IF, IP
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-alpha 1 Fetoprotein antibody [EPR9309]
See all alpha 1 Fetoprotein primary antibodies -
Description
Rabbit monoclonal [EPR9309] to alpha 1 Fetoprotein -
Host species
Rabbit -
Tested applications
Suitable for: Flow Cyt (Intra), WB, IHC-P, ICC/IF, IPmore details -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant fragment within Human alpha 1 Fetoprotein. The exact sequence is proprietary.
-
Positive control
- Human plasma, HepG2 and Human fetal liver lysates, Human moderately differentiated hepatocellular carcinoma and Human poorly differentiated hepatocellular carcinoma tissues, HepG2 cells
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.5% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR9309 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab169552 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt (Intra) |
1/50.
ab172730-Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
|
WB |
1/1000 - 1/10000. Detects a band of approximately 70 kDa (predicted molecular weight: 68 kDa).
|
|
IHC-P |
1/50 - 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
|
|
ICC/IF |
1/100 - 1/250.
|
|
IP |
1/10 - 1/100.
|
Notes |
---|
Flow Cyt (Intra)
1/50. ab172730-Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
WB
1/1000 - 1/10000. Detects a band of approximately 70 kDa (predicted molecular weight: 68 kDa). |
IHC-P
1/50 - 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
ICC/IF
1/100 - 1/250. |
IP
1/10 - 1/100. |
Target
-
Function
Binds copper, nickel, and fatty acids as well as, and bilirubin less well than, serum albumin. Only a small percentage (less than 2%) of the human AFP shows estrogen-binding properties. -
Tissue specificity
Plasma. Synthesized by the fetal liver and yolk sac. -
Sequence similarities
Belongs to the ALB/AFP/VDB family.
Contains 3 albumin domains. -
Developmental stage
Occurs in the plasma of fetuses more than 4 weeks old, reaches the highest levels during the 12th-16th week of gestation, and drops to trace amounts after birth. The serum level in adults is usually less than 40 ng/ml. AFP occurs also at high levels in the plasma and ascitic fluid of adults with hepatoma. -
Post-translational
modificationsIndependent studies suggest heterogeneity of the N-terminal sequence of the mature protein and of the cleavage site of the signal sequence.
Sulfated. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 174 Human
- Omim: 104150 Human
- SwissProt: P02771 Human
- Unigene: 518808 Human
-
Alternative names
- Afp antibody
- AFPD antibody
- Alpha fetoglobulin antibody
see all
Images
-
Immunohistochemical analysis of paraffin embedded human moderately differentiated hepatocellular carcinoma tissue labeling alpha 1 Fetoprotein with ab169552 antibody at 1/50.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
All lanes : Anti-alpha 1 Fetoprotein antibody [EPR9309] (ab169552) at 1/1000 dilution
Lane 1 : Human plasma lysate
Lane 2 : HepG2 lysate
Lane 3 : Human fetal liver lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 68 kDa
Observed band size: 70 kDa why is the actual band size different from the predicted? -
Immunofluorescent analysis of HepG2 cells labeling alpha 1 Fetoprotein with ab169552 at 1/100.
-
Immunoprecipitation. ab169552 at 1/1000 staining alpha 1 Fetoprotein in HepG2 cell lysate immunoprecipitated using ab169552 at 1/10. Predicted band size : 68 kDa.
-
Intracellular Flow Cytometry analysis of HepG2 (human hepatocellular carcinoma) cells labeling alpha 1 Fetoprotein with purified ab169552 at 1/50 dilution (red). The secondary antibody was Goat anti rabbit IgG (Alexa Fluor® 488) at 1/2000 dilution. A Rabbit monoclonal IgG (Black) was used as the isotype control and cells without incubation with primary antibody and secondary antibody (Blue) were used as unlabeled control.
-
Immunohistochemical analysis of paraffin embedded Human poorly differentiated hepatocellular carcinoma tissue labeling alpha 1 Fetoprotein with ab169552 antibody at 1/50.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (10)
ab169552 has been referenced in 10 publications.
- Jiang Z et al. Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors. EMBO Rep 23:e54275 (2022). PubMed: 35437924
- Yang L et al. MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma. Cancer Chemother Pharmacol 87:125-134 (2021). PubMed: 33141330
- Luo M et al. Establishment and characterization of an ovarian yolk sac tumor patient-derived xenograft model. Pediatr Surg Int 37:1031-1040 (2021). PubMed: 34031745
- Chandler RJ et al. Promoterless, Nuclease-Free Genome Editing Confers a Growth Advantage for Corrected Hepatocytes in Mice With Methylmalonic Acidemia. Hepatology 73:2223-2237 (2021). PubMed: 32976669
- Kong XX et al. The Clinicopathological Characteristics of Alpha-Fetoprotein-Producing Adenocarcinoma of the Gastrointestinal Tract-A Single-Center Retrospective Study. Front Oncol 11:635537 (2021). PubMed: 33996549
- Werder RB et al. Adenine base editing reduces misfolded protein accumulation and toxicity in alpha-1 antitrypsin deficient patient iPSC-hepatocytes. Mol Ther 29:3219-3229 (2021). PubMed: 34217893
- Song Q et al. Long non-coding RNA LINC00473 acts as a microRNA-29a-3p sponge to promote hepatocellular carcinoma development by activating Robo1-dependent PI3K/AKT/mTOR signaling pathway. Ther Adv Med Oncol 12:1758835920937890 (2020). PubMed: 32922520
- Song Y et al. Oxytetracycline have the therapeutic efficiency in CD133+ HCC population through suppression CD133 expression by decreasing of protein stability of CD133. Sci Rep 8:16100 (2018). PubMed: 30382122
- Yanagi Y et al. In vivo and ex vivo methods of growing a liver bud through tissue connection. Sci Rep 7:14085 (2017). IHC ; Rat . PubMed: 29074999
- Xin H et al. Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts. PLoS One 9:e85308 (2014). IHC-P ; Human . PubMed: 24416385